ES2159938T3 - Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona. - Google Patents

Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona.

Info

Publication number
ES2159938T3
ES2159938T3 ES98908080T ES98908080T ES2159938T3 ES 2159938 T3 ES2159938 T3 ES 2159938T3 ES 98908080 T ES98908080 T ES 98908080T ES 98908080 T ES98908080 T ES 98908080T ES 2159938 T3 ES2159938 T3 ES 2159938T3
Authority
ES
Spain
Prior art keywords
oral
methyl
decaprenil
benzoquinona
dimetoxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98908080T
Other languages
English (en)
Inventor
Franz Enzmann
Burkhard Lachmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSE Pharmazeutika GmbH
Original Assignee
MSE Pharmazeutika GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSE Pharmazeutika GmbH filed Critical MSE Pharmazeutika GmbH
Application granted granted Critical
Publication of ES2159938T3 publication Critical patent/ES2159938T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35Ketones, e.g. benzophenone
    • A61K8/355Quinones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparado transdérmico, oral o intravenoso de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona que contiene, además de coadyuvantes usuales, una cantidad eficaz de tensioactivo pulmonar.
ES98908080T 1997-02-11 1998-02-11 Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona. Expired - Lifetime ES2159938T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19705231 1997-02-11
CA002280316A CA2280316A1 (en) 1997-02-11 1999-08-13 Transdermal, oral and intravenous formulations of 2,3-dimethoxy-5-methyl-6-dacaprenyl-1,4-benzoquinone

Publications (1)

Publication Number Publication Date
ES2159938T3 true ES2159938T3 (es) 2001-10-16

Family

ID=25681130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98908080T Expired - Lifetime ES2159938T3 (es) 1997-02-11 1998-02-11 Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona.

Country Status (7)

Country Link
US (1) US20020155151A1 (es)
EP (1) EP1007021B1 (es)
AT (1) ATE201988T1 (es)
CA (1) CA2280316A1 (es)
DE (1) DE59800863D1 (es)
ES (1) ES2159938T3 (es)
WO (1) WO1998035660A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878514B1 (en) 1999-03-30 2005-04-12 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
AU3930600A (en) * 1999-03-30 2000-10-16 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
JP4421801B2 (ja) * 2000-05-09 2010-02-24 株式会社カネカ 補酵素qを有効成分とする皮膚用組成物
TW200304372A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
WO2005034945A1 (fr) * 2003-10-11 2005-04-21 Thierry Schwitzguebel Utilisation de la norphenazone et de coenzyme q pour le traitement de l'arthrose, l'arthrite et l'osteo-arthrite
KR101535395B1 (ko) 2004-01-22 2015-07-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
CA2579710C (en) 2004-04-05 2013-01-08 The University Of Tokushima Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same
EP1930025B1 (en) * 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
CA2823407C (en) 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
CA2721071C (en) 2008-04-11 2017-10-17 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
EA201101519A1 (ru) 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
SG10202010355PA (en) * 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムq10の連続注入によるがんの治療方法
CN107979996A (zh) * 2015-04-30 2018-05-01 不莱梅大学 新的皮肤医疗和美容护理产品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073789A (en) * 1988-03-31 1989-10-05 Abbott Laboratories Drug delivery using pulmonary surfactant to facilitate absorption
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
ATE120366T1 (de) * 1990-06-11 1995-04-15 Idi Farmaceutici Spa Aktive bestandteile enthaltende phospholipidische liposome und verfahren zu ihrer herstellung.
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
AU3705695A (en) * 1994-10-26 1996-05-23 Wellcome Foundation Limited, The Pharmaceutical composition comprising atovaquone

Also Published As

Publication number Publication date
EP1007021A1 (de) 2000-06-14
CA2280316A1 (en) 2001-02-13
EP1007021B1 (de) 2001-06-13
ATE201988T1 (de) 2001-06-15
DE59800863D1 (de) 2001-07-19
WO1998035660A1 (de) 1998-08-20
US20020155151A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
ES2159938T3 (es) Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona.
IL140710A0 (en) Pulmonary delivery of active agents
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ZA200102105B (en) Stable concentrated insulin preparations for pulmonary.
PT758248E (pt) Formulacoes para o factor ix
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
DK0812198T3 (da) Stabilisering af prostaglandinpræparater
PL319603A1 (en) Stable aqueous alpha interferon preparations
DK0830145T3 (da) Formuleringer omfattende leflunomid
DE69708121T2 (de) Halogenid-enthaltende insulinzubereitungen
ATE321534T1 (de) Verbesserte liposomale formulierung
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
NO20001415L (no) Farmasøytikum inneholdende vitamin-K-avhengige faktorer
ES2090966T3 (es) Formulaciones liposomicas con piroxicam.
EP1269978A3 (de) Verwendung von Bis-Resorcinyltriazinderivaten in kosmetischen oder dermatologischen Zubereitungen
ATE263576T1 (de) Prostaglandine und benzylalcohol enthaltende lösung
ES2161041T3 (es) Preparado de un tensioactivo pulmonar para instilacion y para la aplicacion oral.
IT8648748A0 (it) Liposomi di coenzima q10.procedimento di preparazione e relative composizioni farmaceutiche

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1007021

Country of ref document: ES